Jean-michel M. Molina
Experienced in Chlamydia

Jean-michel M. Molina

Paris, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Chlamydia
Paris, FR 
OverviewLocationsClinical Research

Overview

Jean-michel Molina practices in Paris, France. Mr. Molina is rated as an Experienced expert by MediFind in the treatment of Chlamydia. His top areas of expertise are HIV/AIDS, Hepatitis, Gonorrhea, Kidney Transplant, and Bone Marrow Transplant.

His clinical research consists of co-authoring 383 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Chlamydia.

Gender
Male

Locations

Paris, France
Other Locations
Port-saint-louis-du-rhone, France
1, Avenue Claude Vellefaux 75010 Paris, Saint-claude-de-diray, 75010, France
Pantin, France
100 Boulevard Du Général Leclerc, Clichy-sous-bois, 92110, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomised Phase II Placebo-controlled Trial of Antiretroviral Therapy (ART) Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies (bNAbs) vs ART Plus Placebo During Primary HIV-1 Infection to Study the Impact on Post-treatment HIV Control.
A Randomised Phase II Placebo-controlled Trial of Antiretroviral Therapy (ART) Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies (bNAbs) vs ART Plus Placebo During Primary HIV-1 Infection to Study the Impact on Post-treatment HIV Control.
Enrollment Status: Recruiting
Publish Date: December 27, 2024
Intervention Type: Drug
Study Phase: Phase 2
Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU ('Autorisation Temporaire d'Utilisation') or or Authorisation for Early Access (AAP). A Prospective Cohort.
Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU ('Autorisation Temporaire d'Utilisation') or or Authorisation for Early Access (AAP). A Prospective Cohort.
Enrollment Status: Completed
Publish Date: May 28, 2025
Intervention Type: Other
An Open-Label, Multi-Centre, Randomised Study to Investigate Integrase Inhibitor Versus Boosted Protease Inhibitor Antiretroviral Therapy for Patients With Advanced HIV Disease
An Open-Label, Multi-Centre, Randomised Study to Investigate Integrase Inhibitor Versus Boosted Protease Inhibitor Antiretroviral Therapy for Patients With Advanced HIV Disease
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: Biktarvy, Symtuza
Study Phase: Phase 3
Combined Prevention of Sexually Transmitted Infections (STIs) in Men Who Have Sex With Men and Using Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC) for HIV Pre-Exposure Prophylaxis (PrEP)
Combined Prevention of Sexually Transmitted Infections (STIs) in Men Who Have Sex With Men and Using Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC) for HIV Pre-Exposure Prophylaxis (PrEP)
Enrollment Status: Completed
Publish Date: July 30, 2024
Intervention Type: Biological, Drug
Study Drugs: Doxycycline, Bexsero® vaccine
Study Phase: Phase 3
A Phase III, Randomized, Multicenter, Open-label, Non-inferiority Study Evaluating the Efficacy, Safety and Tolerability of Switching to Dolutegravir/Lamivudine Fixed Dose Combination in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase III, Randomized, Multicenter, Open-label, Non-inferiority Study Evaluating the Efficacy, Safety and Tolerability of Switching to Dolutegravir/Lamivudine Fixed Dose Combination in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: October 19, 2023
Intervention Type: Drug
Study Drugs: Dolutegravir+Lamivudine, Current antiretroviral regimen
Study Phase: Phase 3
A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: July 19, 2023
Intervention Type: Drug
Study Drugs: Dolutegravir+Lamivudine, Tenofovir alafenamide based regimen
Study Phase: Phase 3
Early Oral Switch Therapy in Low-risk Staphylococcus Aureus Bloodstream Infection
Early Oral Switch Therapy in Low-risk Staphylococcus Aureus Bloodstream Infection
Enrollment Status: Completed
Publish Date: May 27, 2020
Intervention Type: Drug
Study Phase: Phase 3
Phase III Open-label Randomized Multicenter Trial to Assess the Non-inferiority of Raltegravir Compared With EFavirenz, Both in Combination With LAmivudine and TEnofovir, in ART-naïve HIV-1-infected Patients Receiving Rifampin for Active TuBerculosis
Phase III Open-label Randomized Multicenter Trial to Assess the Non-inferiority of Raltegravir Compared With EFavirenz, Both in Combination With LAmivudine and TEnofovir, in ART-naïve HIV-1-infected Patients Receiving Rifampin for Active TuBerculosis
Enrollment Status: Completed
Publish Date: December 31, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 7 Less Clinical Trials

383 Total Publications

Trajectories of Chemsex Engagement Across Time Among PrEP-Using Men Who Have Sex with Men: Results from the French ANRS-Prévenir Cohort.
Trajectories of Chemsex Engagement Across Time Among PrEP-Using Men Who Have Sex with Men: Results from the French ANRS-Prévenir Cohort.
Journal: International journal of sexual health : official journal of the World Association for Sexual Health
Published: August 22, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Molina's expertise for a condition
ConditionClose
    View All 41 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile